ADVANCED PANCREATIC CANCER

This early-phase trial tests an experimental drug called ES502 in people with advanced pancreatic cancer that has a specific genetic change (RAS G12V) and who have run out of standard treatments. ES502 is a lab-made protein designed to guide the body's immune T-cells to attack ca…

This early-phase study tests a new radioactive drug called NRT6008, given alongside standard chemotherapy, for people with advanced pancreatic cancer that cannot be removed by surgery or has spread to nearby lymph nodes. The trial will enroll 58 adults to find the safest dose and…

This early-phase trial tests a combination of three drugs—regorafenib, toripalimab, and albumin-bound paclitaxel—as a third-line treatment for people with advanced pancreatic cancer that has spread or cannot be removed. The study aims to find the safest dose and see if the combo …

This study tests a new drug called LM-108, given with an immunotherapy (penpulimab) and two chemotherapy drugs, in people with advanced pancreatic cancer. The goal is to see if the combination is safe and can shrink tumors or slow the disease. About 72 adults with advanced pancre…

This early study tests a new treatment called hV01, a virus modified to attack cancer cells and boost the immune system. It is for people with advanced pancreatic cancer that has not responded to standard treatments. The goal is to see if the virus can shrink tumors and control t…

This early-phase trial tests a combination of two immune cell therapies—dendritic cells and CAR-T cells—both engineered to target a protein called Claudin18.2 found on some pancreatic cancer cells. The goal is to see if this dual approach is safe and can shrink tumors in people w…

This early trial tests a new treatment called SY001, which uses a patient's own immune cells (macrophages) engineered to attack cancer cells that have a protein called mesothelin. The study includes just 2 people with advanced ovarian or pancreatic cancer who have not responded t…

This early-phase study is testing whether adding low-dose radiation and an immunotherapy drug called pucotenlimab to standard chemotherapy can help control advanced pancreatic cancer. Ten adults with pancreatic cancer who haven't had prior immunotherapy will receive the combinati…

This study tests new drug combinations (ADC drugs alone or with other therapies) in 160 people with advanced pancreatic cancer that has spread or cannot be removed. The goal is to find safe doses and see if tumors shrink. Participants must be 18-75, in good overall health, and ha…

This trial tests a personalized cell therapy for advanced pancreatic cancer. Patients receive their own immune cells that have been engineered to recognize and attack cancer cells with a specific mutation (KRAS G12V). The study enrolls 30 people whose tumors carry this mutation a…

This clinical trial is testing a new biological therapy called GAIA-102, alone or combined with the immunotherapy pembrolizumab, for people with advanced stomach or pancreatic cancer that has spread and caused fluid buildup in the abdomen (malignant ascites). The study has two pa…

This study looks at the genes of 750 people with advanced or metastatic pancreatic cancer. The goal is to find specific genetic changes that could help doctors choose better treatments, like targeted drugs or chemotherapy combinations. Participants must have a tumor sample availa…